Sorrento gets US FDA nod for Phase 1 clinical trial of neutralising antibody in COVID-19 patients
Sorrento had earlier informed that COVI-GUARD (STI-1499) demonstrated 100 per cent in vitro neutralizing effect against SARS-CoV-2…
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.